GO:1990180 mitochondrial tRNA 3'-end processing: RNA Maturation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990180 describes the biological process that converts the 3' end of a mitochondrial pre-tRNA into the mature tRNA 3' terminus inside the mitochondrion.
• The process is essential for mitochondrial protein synthesis because only correctly 3'-processed tRNAs can accept an amino acid and function in translation.
• Key enzymes include ELAC2 (RNase Z), which performs endonucleolytic 3' cleavage, and additional factors that trim, repair, or edit the 3' terminus.
• Defects in mitochondrial tRNA 3'-end processing are linked to human disease, including hypertrophic cardiomyopathy and mitochondrial tRNA(Ala) 3'-end metabolism deficiency.
• The pathway is studied with RNA-seq, Northern blotting, in vitro processing assays, mitochondrial tRNA sequencing, and CRISPR-based models.
• CRISPR knockout, point-mutation, knock-in, and overexpression cell models allow causal testing of processing factors and disease variants.
Description
GO:1990180, mitochondrial tRNA 3'-end processing, is the biological process in which the 3' end of a pre-tRNA molecule is converted to that of a mature tRNA inside the mitochondrion. Mitochondria contain their own genome and a dedicated translation system, and their tRNAs are transcribed as precursor molecules that must be processed at both ends before they can participate in protein synthesis. The 3' end is particularly important because the universal CCA terminus that accepts the amino acid is added or repaired after 3' processing, and errors at this step can block mitochondrial translation. The process is carried out by a small set of nuclear-encoded enzymes that are imported into mitochondria, including the endonuclease ELAC2 (RNase Z) and additional trimming or repair activities. Because mitochondrial tRNAs are encoded by a compact genome with few intergenic spacers, 3'-end processing is tightly coupled to transcription and to the removal of flanking sequences from polycistronic transcripts. Defects in this pathway have been associated with human disease, including hypertrophic cardiomyopathy caused by ELAC2 mutations and mitochondrial tRNA(Ala) 3'-end metabolism deficiency. For researchers, GO:1990180 provides a precise annotation for experiments that measure mitochondrial tRNA maturation, enzyme activity, and disease variant effects. It is also a useful entry point for functional genomics because loss of 3'-end processing can be detected by mitochondrial tRNA sequencing, Northern blotting, and mitochondrial translation assays.
mitochondrial tRNA 3'-end processing At A Glance
| GO ID | GO:1990180 |
|---|---|
| GO term | mitochondrial tRNA 3'-end processing |
| Ontology | biological_process |
| Synonym | tRNA 3'-end processing in mitochondria; tRNA 3' processing in mitochondria; tRNA 3' processing in mitochondrion |
| Definition | The process in which the 3' end of a pre-tRNA molecule is converted to that of a mature tRNA in the mitochondrion. |
| Major function | Maturation of mitochondrial pre-tRNA 3' termini for aminoacylation and mitochondrial translation. |
| Key enzymes | ELAC2 (RNase Z), mitochondrial RNase P components, and 3' repair/editing activities. |
| Cellular location | Mitochondrion, including mitochondrial matrix and inner membrane-associated compartments. |
| Disease relevance | Hypertrophic cardiomyopathy, mitochondrial tRNA(Ala) 3'-end metabolism deficiency, and other mitochondrial translation defects. |
| Research methods | In vitro processing assays, Northern blotting, mitochondrial tRNA sequencing, RNA-seq, and CRISPR models. |
What Is GO:1990180?
In simple terms, GO:1990180 is the mitochondrial version of trimming the tail end of a tRNA molecule so that it becomes fully functional. More formally, it is the biological process in which the 3' end of a pre-tRNA molecule is converted to that of a mature tRNA in the mitochondrion. This includes the endonucleolytic removal of 3' extensions, subsequent trimming or repair events needed to generate a mature 3' terminus, and the steps that prepare the tRNA for CCA addition and aminoacylation. The process is distinct from nuclear tRNA 3' processing because it occurs inside mitochondria and uses a partially distinct set of enzymes and substrates.
Why Is mitochondrial tRNA 3'-end processing Important in Cell Biology?
Mitochondrial tRNA 3'-end processing is important because it is a required step in the biogenesis of every mitochondrial tRNA and therefore in mitochondrial protein synthesis. Without correct 3' maturation, tRNAs cannot be aminoacylated efficiently, mitochondrial translation is impaired, and oxidative phosphorylation complexes cannot be assembled properly. This process is also a point of vulnerability in human disease: mutations in ELAC2 impair mitochondrial tRNA 3'-end processing and have been associated with hypertrophic cardiomyopathy, while defects in mitochondrial tRNA(Ala) 3'-end metabolism cause a distinct deficiency state. Studying GO:1990180 therefore connects basic RNA enzymology to mitochondrial disease mechanisms and to potential therapeutic targets.
• Required for maturation of mitochondrial tRNAs before they can function in translation.
• Provides the correct 3' terminus for CCA addition and aminoacylation.
• Supports mitochondrial protein synthesis and oxidative phosphorylation.
• Links to hypertrophic cardiomyopathy through ELAC2 mutations.
• Links to mitochondrial tRNA(Ala) 3'-end metabolism deficiency.
• Helps explain tissue-specific mitochondrial disease phenotypes.
• Provides a measurable readout for mitochondrial RNA processing defects.
• Enables functional testing of disease-associated variants in processing enzymes.
• Connects RNA processing to mitochondrial genome expression and homeostasis.
• Offers a target area for CRISPR-based disease modeling and therapeutic screening.
What Happens During mitochondrial tRNA 3'-end processing?
Transcription and release of mitochondrial pre-tRNAs
In simple terms: Mitochondrial tRNAs are first made as longer precursor RNAs that must be cut out of a larger transcript.
Mitochondrial tRNAs are transcribed as part of long polycistronic precursor RNAs from the mitochondrial genome. Before 3'-end processing can occur, the pre-tRNA must be released from these precursors, often through flanking cleavage events that separate individual tRNA molecules. This coupling means that 3'-end processing is not an isolated event but part of a coordinated maturation pathway for mitochondrial RNAs.
Endonucleolytic cleavage of the 3' extension by ELAC2
In simple terms: An enzyme called ELAC2 cuts the extra tail off the 3' end of the pre-tRNA.
The central step in mitochondrial tRNA 3'-end processing is endonucleolytic cleavage of the 3' extension by ELAC2, also known as RNase Z. ELAC2 removes the 3' trailer to generate a pre-tRNA with a defined 3' terminus that can be further matured. Mutations in ELAC2 that impair this cleavage have been associated with hypertrophic cardiomyopathy, demonstrating the physiological importance of this step. Structural and biochemical studies have clarified how human ELAC2 recognizes mitochondrial pre-tRNA substrates and positions them for cleavage.
Trimming, repair, and editing at the 3' terminus
In simple terms: After the main cut, additional enzymes may trim, repair, or edit the 3' end to make it exactly right.
Following endonucleolytic cleavage, the 3' terminus may require additional trimming, repair, or editing to reach its mature form. These activities ensure that the tRNA ends at the correct position and can accept the CCA sequence needed for aminoacylation. The balance between cleavage and repair activities is important because incorrect 3' ends can reduce tRNA function and mitochondrial translation.
CCA addition and aminoacylation readiness
In simple terms: Once the 3' end is correct, the tRNA can receive the CCA tail and be loaded with an amino acid.
Mature mitochondrial tRNAs require a 3' CCA terminus for aminoacylation, and this CCA sequence is added or repaired after 3' processing. The correct 3' end generated by GO:1990180 is therefore a prerequisite for charging the tRNA with its amino acid. Defects in 3'-end processing can indirectly impair aminoacylation and mitochondrial translation even when the tRNA sequence itself is normal.
Quality control and degradation of aberrant tRNAs
In simple terms: If the 3' end cannot be processed correctly, the tRNA may be recognized as faulty and removed.
Mitochondrial tRNA maturation is monitored by quality control pathways that can degrade aberrant or improperly processed tRNAs. When 3'-end processing is impaired, unprocessed or misprocessed tRNAs may accumulate and trigger turnover or stress responses. This quality control layer helps explain why processing defects can produce both loss of functional tRNA and toxic accumulation of intermediates.
Integration with mitochondrial translation
In simple terms: Correctly processed tRNAs are delivered to the mitochondrial ribosome to build proteins.
Once 3'-end processing is complete, mature mitochondrial tRNAs participate in mitochondrial translation at the ribosome. This step connects GO:1990180 to the synthesis of oxidative phosphorylation subunits and to cellular energy metabolism. Because mitochondrial translation is essential for respiratory chain function, defects in 3'-end processing can manifest as broad mitochondrial dysfunction.
Key Genes Involved in GO:1990180 mitochondrial tRNA 3'-end processing
The genes and proteins below are the main factors experimentally linked to mitochondrial tRNA 3'-end processing, its regulation, or its disease consequences.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ELAC2 | Endonucleolytic cleavage of mitochondrial pre-tRNA 3' extensions (RNase Z) | Disease variants and catalytic mechanism studies |
| TRMT10C | Mitochondrial tRNA methyltransferase component linked to tRNA maturation | Processing and modification cross-talk |
| PRORP | Mitochondrial RNase P protein subunit involved in tRNA 5' processing | Coordinated 5' and 3' maturation |
| TRMT5 | Mitochondrial tRNA modification enzyme | Modification-dependent processing efficiency |
| MTPAP | Mitochondrial poly(A) polymerase that adds 3' tails | 3' end metabolism and tRNA stability |
| PDE12 | Mitochondrial deadenylase that removes 3' poly(A) tails | 3' end trimming and repair |
| TRNT1 | CCA-adding enzyme for tRNA 3' termini | CCA addition after 3' processing |
| TRIT1 | Mitochondrial tRNA isopentenyltransferase | Modification and processing interplay |
| NSUN2 | RNA methyltransferase with mitochondrial tRNA links | Modification-dependent tRNA stability |
| PUS1 | Pseudouridine synthase acting on tRNAs | Processing and modification coordination |
| TRMU | Mitochondrial tRNA modification enzyme | Disease-linked tRNA maturation |
| GTPBP3 | Mitochondrial tRNA modification factor | Mitochondrial translation and disease |
| MTO1 | Mitochondrial tRNA modification factor | Mitochondrial translation and disease |
| TRUB2 | Mitochondrial tRNA pseudouridine synthase | 3' end maturation and modification |
| RPUSD3 | Mitochondrial tRNA pseudouridine synthase | Processing and modification cross-talk |
| RPUSD4 | Mitochondrial tRNA pseudouridine synthase | Processing and modification cross-talk |
| TRMT2B | Mitochondrial tRNA methyltransferase | tRNA maturation and stability |
How Is mitochondrial tRNA 3'-end processing Regulated?
Mitochondrial tRNA 3'-end processing is regulated at multiple levels, including substrate availability, enzyme expression, and post-transcriptional modification of the tRNA itself. The activity of ELAC2 and other processing enzymes must be coordinated with transcription of the mitochondrial genome and with 5' processing by RNase P components. tRNA modifications can influence processing efficiency and stability, and quality control pathways can degrade improperly processed tRNAs. Disease-associated mutations in processing factors can alter this regulation and lead to tissue-specific mitochondrial dysfunction.
mitochondrial tRNA 3'-end processing and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ELAC2 | Hypertrophic cardiomyopathy; impaired mitochondrial tRNA 3'-end processing | Knockout and point-mutation cell models |
| MTPAP | 3' end metabolism and tRNA stability defects | Knockout and overexpression models |
| TRNT1 | CCA addition defects affecting tRNA maturation | Point-mutation and knockout models |
| PDE12 | 3' trimming and repair defects | Knockout and tagged knock-in models |
| ELAC2 | Mitochondrial tRNA(Ala) 3'-end metabolism deficiency | Patient-variant knock-in models |
Hypertrophic cardiomyopathy and ELAC2 mutations
Mutations in ELAC2 have been associated with hypertrophic cardiomyopathy and were shown to impair mitochondrial tRNA 3'-end processing. This links a specific RNA processing defect to a clinically important cardiac phenotype. Functional studies of ELAC2 variants can help explain why mitochondrial translation defects produce cardiomyopathy.
Mitochondrial tRNA(Ala) 3'-end metabolism deficiency
Defects in mitochondrial tRNA(Ala) 3'-end metabolism have been described as a distinct deficiency state, with mechanistic insights into how 3' end processing fails. This condition illustrates that even a single mitochondrial tRNA species can be affected by 3'-end processing defects. It also provides a model for studying the molecular consequences of impaired 3' maturation.
Mitochondrial disease and oxidative phosphorylation defects
Because mitochondrial tRNA 3'-end processing is required for mitochondrial translation, defects in this process can cause broad oxidative phosphorylation deficiency. Patients may present with multi-system mitochondrial disease, and the severity depends on the specific enzyme and tissue. Understanding GO:1990180 helps interpret variants in processing factors identified by clinical sequencing.
Cancer and metabolic reprogramming
Mitochondrial translation and tRNA maturation are increasingly recognized as relevant to cancer metabolism, although direct evidence for GO:1990180 in cancer remains limited. Researchers can use mitochondrial tRNA processing readouts to test whether cancer-associated metabolic states depend on this pathway. Such studies should be designed carefully to avoid overstating causal links.
From mitochondrial tRNA 3'-end processing-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is ELAC2 required for mitochondrial tRNA 3'-end processing? | ELAC2 knockout cell line |
| Do disease variants impair catalytic activity? | ELAC2 point-mutation knock-in |
| Can wild-type ELAC2 rescue processing defects? | ELAC2 overexpression |
| Where does ELAC2 localize and interact? | Tagged knock-in with imaging and proteomics |
| Does loss of 3' processing alter mitochondrial translation? | Knockout plus mitochondrial translation assays |
| Can candidate genes modify the processing phenotype? | CRISPR library screening |
How to Study the mitochondrial tRNA 3'-end processing Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro processing assay | 3' cleavage activity on pre-tRNA | Testing ELAC2 variants |
| Northern blotting | tRNA size and abundance | Detecting processing defects |
| Mitochondrial tRNA sequencing | 3' terminus mapping | Defining misprocessing events |
| RNA-seq | Mitochondrial transcript levels | Screening processing factors |
| Proteomics | Oxidative phosphorylation subunit levels | Linking processing to translation |
| Mitochondrial translation assay | Newly synthesized mitochondrial proteins | Functional validation |
| Imaging | Enzyme localization and mitochondrial morphology | Tagged knock-in studies |
| CRISPR screening | Candidate modifier genes | Pathway discovery |
In vitro processing assays
In vitro processing assays use labeled pre-tRNA substrates incubated with mitochondrial extracts or recombinant enzymes to measure 3' cleavage activity. These assays can test the effects of disease variants on ELAC2 function and define substrate requirements. They are a direct way to study GO:1990180 at the biochemical level.
Northern blotting and mitochondrial tRNA sequencing
Northern blotting can detect changes in mitochondrial tRNA size and abundance caused by 3'-end processing defects. Mitochondrial tRNA sequencing provides higher-resolution mapping of 3' termini and can reveal misprocessing. Together these methods connect enzyme activity to steady-state tRNA maturation.
RNA-seq and mitochondrial transcriptome analysis
RNA-seq can quantify mitochondrial transcripts and detect accumulation of unprocessed precursors. Differential expression and junction analysis can identify processing intermediates in knockout or mutant cells. This approach is useful for screening candidate processing factors.
Proteomics and mitochondrial translation assays
Proteomics can measure the abundance of oxidative phosphorylation subunits whose synthesis depends on mitochondrial translation. Mitochondrial translation assays using labeled amino acids directly test whether 3'-end processing defects impair protein synthesis. These readouts link GO:1990180 to mitochondrial function.
How CRISPR Can Be Used to Study GO:1990180 mitochondrial tRNA 3'-end processing
Knockout
CRISPR knockout of ELAC2 or other processing factors can abolish mitochondrial tRNA 3'-end processing and reveal downstream effects on translation and cell growth. Knockout models are useful for testing whether a candidate gene is required for the pathway. They also provide a clean background for rescue experiments.
Point Mutation
Point-mutation knock-in models can reproduce disease-associated variants in ELAC2 and other processing genes. These models allow researchers to distinguish loss-of-function from other mechanisms. They are especially valuable when the variant is found in patients but its effect is unknown.
Knock-in
Tagged knock-in of processing enzymes enables localization, interaction, and dynamic studies in living cells. Knock-in of reporter or affinity tags can support proteomics and imaging of the processing machinery. This approach helps define where and when 3'-end processing occurs.
Overexpression
Overexpression of wild-type or mutant processing enzymes can test sufficiency and dominant-negative effects. It is useful for rescue experiments in knockout backgrounds. Overexpression models also support biochemical purification of processing complexes.
How EDITGENE Supports mitochondrial tRNA 3'-end processing Research
Researchers studying mitochondrial tRNA 3'-end processing-related genes often need to determine whether a candidate gene is causally involved in the pathway or whether a disease variant directly impairs enzyme function. EDITGENE provides CRISPR-based cell models and screening services designed to answer these questions with reproducible, publication-ready data.
Contact EDITGENE today to design your custom CRISPR model for mitochondrial tRNA 3'-end processing research.
Frequently Asked Questions About mitochondrial tRNA 3'-end processing
What is mitochondrial tRNA 3'-end processing?
It is the biological process GO:1990180 in which the 3' end of a mitochondrial pre-tRNA is converted to that of a mature tRNA.
What genes are involved in mitochondrial tRNA 3'-end processing?
Key genes include ELAC2, MTPAP, PDE12, TRNT1, and several mitochondrial tRNA modification enzymes.
Which enzyme cleaves the 3' end of mitochondrial pre-tRNA?
ELAC2, also known as RNase Z, performs the endonucleolytic cleavage of the 3' extension.
Why is mitochondrial tRNA 3'-end processing important?
It is required for tRNA maturation, aminoacylation, and mitochondrial protein synthesis.
What diseases are linked to defects in this process?
Hypertrophic cardiomyopathy and mitochondrial tRNA(Ala) 3'-end metabolism deficiency have been linked to processing defects.
How is mitochondrial tRNA 3'-end processing studied?
Common methods include in vitro processing assays, Northern blotting, mitochondrial tRNA sequencing, RNA-seq, and CRISPR models.
What is the role of ELAC2 in mitochondrial tRNA processing?
ELAC2 cleaves the 3' trailer of mitochondrial pre-tRNAs, and its mutations impair processing.
Can CRISPR be used to study mitochondrial tRNA 3'-end processing?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models can test processing factors and disease variants.
What happens if mitochondrial tRNA 3'-end processing fails?
Unprocessed tRNAs accumulate, aminoacylation and mitochondrial translation are impaired, and mitochondrial disease can result.
What is the GO ID for mitochondrial tRNA 3'-end processing?
The GO ID is GO:1990180.
Conclusion
GO:1990180, mitochondrial tRNA 3'-end processing, is a focused but essential biological process that connects mitochondrial RNA maturation to protein synthesis and human disease. The pathway is defined by endonucleolytic cleavage of pre-tRNA 3' extensions, followed by trimming, repair, and CCA addition steps that prepare tRNAs for aminoacylation. Disease links, especially ELAC2-related hypertrophic cardiomyopathy and mitochondrial tRNA(Ala) 3'-end metabolism deficiency, make this process a compelling area for functional genomics. CRISPR-based models and mitochondrial RNA methods now allow researchers to test causality and explore therapeutic hypotheses with increasing precision.
References
- 1. Ji Y et al.. 2021. Mechanistic insights into mitochondrial tRNA(Ala) 3'-end metabolism deficiency.. J Biol Chem 297(1):100816 PMID: 34023389
- 2. Bhatta A et al.. 2025. Molecular basis of human nuclear and mitochondrial tRNA 3' processing.. Nat Struct Mol Biol 32(4):613-624 PMID: 39747487
- 3. Levinger L et al.. 2004. Mitochondrial tRNA 3' end metabolism and human disease.. Nucleic Acids Res 32(18):5430-41 PMID: 15477393
- 4. Schürer H et al.. 2001. This is the end: processing, editing and repair at the tRNA 3'-terminus.. Biol Chem 382(8):1147-56 PMID: 11592395
- 5. Saoura M et al.. 2019. Mutations in ELAC2 associated with hypertrophic cardiomyopathy impair mitochondrial tRNA 3'-end processing.. Hum Mutat 40(10):1731-1748 PMID: 31045291
- 6. Rossmanith W et al.. 1995. Human mitochondrial tRNA processing.. J Biol Chem 270(21):12885-91 PMID: 7759547
- 7. Rossmanith W. 2012. Of P and Z: mitochondrial tRNA processing enzymes.. Biochim Biophys Acta 1819(9-10):1017-26 PMID: 22137969
- 8. Rammelt C et al.. 2016. Repairing tRNA termini: News from the 3' end.. RNA Biol 13(12):1182-1188 PMID: 27661287
